Literature DB >> 17076975

Increasing importance of dry eye syndrome and the ideal artificial tear: consensus views from a roundtable discussion.

Penny A Asbell1.   

Abstract

BACKGROUND: Dry eye syndrome is a highly prevalent, yet largely under diagnosed, condition that can substantially affect quality of life. Left untreated, dry eye is associated with chronic eye pain and increased risk of ocular surface disease. Current demographic changes and lifestyle factors indicate that the dry eye syndrome patient population will increase significantly, ensuring that general practitioners and ophthalmic clinicians alike will experience more patients presenting with dry eye symptoms. Greater public and practitioner awareness of emerging research, technologies, and therapies is crucial to ensuring appropriate interventions to meet specific patient needs and result in clinically favorable outcomes. ROUNDTABLE ASSEMBLY: In August 2005, a team of ocular surface experts convened for a 1-day roundtable session to discuss the latest information on diagnosing and treating dry eye syndrome and real-world issues in artificial tear therapy, including preservative use. ROUNDTABLE DISCUSSION: The discussion centered on the mild to moderate dry eye patient and critical features of the ideal artificial tear, which are preservative-free formulation, protection from microbial contamination, cost-effective, non-blurring, and easy to use. Products that match this profile have the advantage of being able to benefit the myriad of patients who comprise the dry eye syndrome population. Ocular surface health should always remain a top priority. Preferred Practice Pattern Dry Eye Syndrome Medical Treatment guidelines should be modified to recommend the use of preservative-free formula artificial tear products for all levels of dry eye conditions in consideration of the medical benefit they offer to dry eye syndrome sufferers.
CONCLUSION: The growing prevalence of dry eye syndrome demands increased attention. Further research, enhanced diagnostic tests, increased use of preservative-free artificial tear formulations as first-line therapy, greater patient-practitioner interaction, and patient education are warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17076975     DOI: 10.1185/030079906X132640

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  12 in total

Review 1.  Artificial tears potpourri: a literature review.

Authors:  Majid Moshirfar; Kasey Pierson; Kamalani Hanamaikai; Luis Santiago-Caban; Valliammai Muthappan; Samuel F Passi
Journal:  Clin Ophthalmol       Date:  2014-07-31

Review 2.  The role and treatment of inflammation in dry eye disease.

Authors:  Ayse Yagci; Canan Gurdal
Journal:  Int Ophthalmol       Date:  2014-07-26       Impact factor: 2.031

3.  Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease.

Authors:  Amalia Enríquez-de-Salamanca; Evangelina Castellanos; Michael E Stern; Itziar Fernández; Ester Carreño; Carmen García-Vázquez; Jose M Herreras; Margarita Calonge
Journal:  Mol Vis       Date:  2010-05-19       Impact factor: 2.367

4.  Efficacy of two-month treatment with Xiloial eyedrops for discomfort from disposable soft contact lenses.

Authors:  Piera Versura; Vincenzo Profazio; Nicole Balducci; Emilio C Campos
Journal:  Clin Ophthalmol       Date:  2010-09-20

5.  Omega-3 fatty acid supplementation improves dry eye symptoms in patients with glaucoma: results of a prospective multicenter study.

Authors:  Jesús Tellez-Vazquez
Journal:  Clin Ophthalmol       Date:  2016-04-05

Review 6.  The correct diagnosis and therapeutic management of tear dysfunction: recommendations of the P.I.C.A.S.S.O. board.

Authors:  Maurizio Rolando; Emilia Cantera; Rita Mencucci; Pierangela Rubino; Pasquale Aragona
Journal:  Int Ophthalmol       Date:  2017-04-10       Impact factor: 2.031

7.  The use of preservatives in dry eye drops.

Authors:  Karen Walsh; Lyndon Jones
Journal:  Clin Ophthalmol       Date:  2019-08-01

8.  Management of moderate-to-severe dry eye disease using chitosan-N-acetylcysteine (Lacrimera®) eye drops: a retrospective case series.

Authors:  Johannes Nepp; Wolfgang Knoetzl; Anna Prinz; Sonja Hoeller; Martin Prinz
Journal:  Int Ophthalmol       Date:  2020-03-02       Impact factor: 2.031

Review 9.  Dry eye: why artificial tears are not always the answer.

Authors:  Minji Kim; Yonghoon Lee; Divy Mehra; Alfonso L Sabater; Anat Galor
Journal:  BMJ Open Ophthalmol       Date:  2021-04-08

Review 10.  Algorithmic approach to diagnosis and management of post-refractive surgery dry eye disease.

Authors:  Sharon D'Souza; Edwin James; Rishi Swarup; Sheetal Mahuvakar; Aditya Pradhan; Krati Gupta
Journal:  Indian J Ophthalmol       Date:  2020-12       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.